Ligand Pharma Partner Viking Therapeutics Prices IPO At $8.00/shr - Quick Facts

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) partner Viking Therapeutics Inc. (VKTX) announced that it has priced its initial public offering of 3 million shares of its common stock at an initial offering price to the public of $8.00 per share.

Viking has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the same price to cover over-allotments, if any. Viking expects the shares to begin trading on the Nasdaq Capital Market on April 29, 2015 under the ticker symbol "VKTX". Viking expects the offering to close on May 4, 2015, subject to the satisfaction of customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as the sole book-running manager for the offering. Feltl and Company, Inc. is serving as co-manager for the offering.